About Aldo-keto reductase family 1 member B10
Aldo-keto reductase family 1 member B10 (AKR1B10) is a protein
from Homo sapiens identified by UniProt accession
O60218, 316 residues long.
MolForge cross-references it against 0 known binders and
223 disease associations.
Target properties
| Protein name | Aldo-keto reductase family 1 member B10 |
| UniProt accession | O60218 |
| Gene | AKR1B10 |
| Organism | Homo sapiens |
| Length | 316 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (223)
Diseases linked to this target (Open Targets).
- diastolic blood pressure · score 0.39
- systolic blood pressure · score 0.39
- Agents acting on the renin-angiotensin system use measurement · score 0.36
- hypertension · score 0.36
- cardiovascular disease · score 0.27
- Calcium channel blocker use measurement · score 0.23
- lung adenocarcinoma · score 0.23
- white matter growth measurement · score 0.22
- blood pressure · score 0.21
- cutaneous melanoma · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60218-F1 | alphafold | PREDICTED | 97.74 | — |
Amino-acid sequence (316 residues)
MATFVELSTK AKMPIVGLGT WKSPLGKVKE AVKVAIDAGY RHIDCAYVYQ NEHEVGEAIQ EKIQEKAVKR EDLFIVSKLW PTFFERPLVR KAFEKTLKDL KLSYLDVYLI HWPQGFKSGD DLFPKDDKGN AIGGKATFLD AWEAMEELVD EGLVKALGVS NFSHFQIEKL LNKPGLKYKP VTNQVECHPY LTQEKLIQYC HSKGITVTAY SPLGSPDRPW AKPEDPSLLE DPKIKEIAAK HKKTAAQVLI RFHIQRNVIV IPKSVTPARI VENIQVFDFK LSDEEMATIL SFNRNWRACN VLQSSHLEDY PFNAEY
Explore Aldo-keto reductase family 1 member B10 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets